15-lipoxygenase-1-mediated metabolism of docosahexaenoic acid is required for syndecan-1 signaling and apoptosis in prostate cancer cells

Carcinogenesis

Volumn 34, Issue 1, 2013, Pages 176-182

  Hu, Yunping ^a   Sun, Haiguo ^a   O'Flaherty, Joseph T ^a   Edwards, Iris J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 LIPOXYGENASE 1; 15 LIPOXYGENASE 2; ARACHIDONATE 15 LIPOXYGENASE; BAICALEIN; CASPASE 3; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; LUTEOLIN; NORDIHYDROGUAIARETIC ACID; PROTEIN KINASE B; SYNDECAN 1; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; FATTY ACID METABOLISM; GENE SILENCING; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION;

APOPTOSIS; ARACHIDONATE 15-LIPOXYGENASE; DOCOSAHEXAENOIC ACIDS; HUMANS; MALE; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION; SYNDECAN-1;

EID: 84872170168     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs324     Document Type: Article

References (55)

1. Augustsson, K. et al. (2003) A prospective study of intake of fish and marine fatty acids and prostate cancer. Cancer Epidemiol. Biomarkers Prev., 12, 64-67.
2. Leitzmann, M.F. et al. (2004) Dietary intake of n-3 and n-6 fatty acids and the risk of prostate cancer. Am. J. Clin. Nutr., 80, 204-216.
3. McEntee, M.F. et al. (2008) Dietary n-3 polyunsaturated fatty acids enhance hormone ablation therapy in androgen-dependent prostate cancer. Am. J. Pathol., 173, 229-241.
4. Kuriki, K. et al. (2007) Breast cancer risk and erythrocyte compositions of n-3 highly unsaturated fatty acids in Japanese. Int. J. Cancer, 121, 377-385.
5. Patterson, R.E. et al. (2011) Marine fatty acid intake is associated with breast cancer prognosis. J. Nutr., 141, 201-206.
6. Pot, G.K. et al. (2008) Opposing associations of serum n-3 and n-6 polyunsaturated fatty acids with colorectal adenoma risk: an endoscopy-based case-control study. Int. J. Cancer, 123, 1974-1977.
7. Berg, J.P. et al. (1994) Longchain serum fatty acids and risk of thyroid cancer: a population-based case-control study in Norway. Cancer Causes Control, 5, 433-439.
8. Bougnoux, P. et al. (2009) Improving outcome of chemotherapy of metastatic breast cancer by docosahexaenoic acid: a phase II trial. Br. J. Cancer, 101, 1978-1985.
9. Bougnoux, P. et al. (2010) Fatty acids and breast cancer: sensitization to treatments and prevention of metastatic re-growth. Prog. Lipid Res., 49, 76-86.
10. Gleissman, H. et al. (2011) Omega-3 fatty acid supplementation delays the progression of neuroblastoma in vivo. Int. J. Cancer, 128, 1703-1711.
11. Wu, M. et al. (2005) Omega-3 polyunsaturated fatty acids attenuate breast cancer growth through activation of a neutral sphingomyelinase-mediated pathway. Int. J. Cancer, 117, 340-348.
12. Hu, Y. et al. (2010) Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia, 12, 826-836.
13. Sun, H. et al. (2008) Peroxisome proliferator-activated receptor gammamediated up-regulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res., 68, 2912-2919.
14. Edwards, I. J. et al. (2008) In vivo and in vitro regulation of syndecan 1 in prostate cells by n-3 polyunsaturated fatty acids. J. Biol. Chem., 283, 18441-18449.
15. Yamagami, T. et al. (2009) Docosahexaenoic acid induces dose dependent cell death in an early undifferentiated subtype of acute myeloid leukemia cell line. Cancer Biol. Ther., 8, 331-337.
16. Blanckaert, V. et al. (2010) Docosahexaenoic acid intake decreases proliferation, increases apoptosis and decreases the invasive potential of the human breast carcinoma cell line MDA-MB-231. Int. J. Oncol., 36, 737-742.
17. Kang, K.S. et al. (2010) Docosahexaenoic acid induces apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species formation and caspase 8 activation. PLoS ONE, 5, e10296.
18. Ding, W.Q. et al. (2007) Phospholipid hydroperoxide glutathione peroxidase plays a role in protecting cancer cells from docosahexaenoic acidinduced cytotoxicity. Mol. Cancer Ther., 6, 1467-1474.
19. Wall, R. et al. (2010) Fatty acids from fish: the anti-inflammatory potential of long-chain omega-3 fatty acids. Nutr. Rev., 68, 280-289.
20. Spencer, L. et al. (2009) The effect of omega-3 FAs on tumour angiogenesis and their therapeutic potential. Eur. J. Cancer, 45, 2077-2086.
21. Calder, P.C. (2007) Immunomodulation by omega-3 fatty acids. Prostaglandins Leukot. Essent. Fatty Acids, 77, 327-335.
22. Serhan, C.N. (2005) Novel eicosanoid and docosanoid mediators: resolvins, docosatrienes, and neuroprotectins. Curr. Opin. Clin. Nutr. Metab. Care, 8, 115-121.
23. Sun, Y.P. et al. (2007) Resolvin D1 and its aspirin-triggered 17R epimer. Stereochemical assignments, anti-inflammatory properties, and enzymatic inactivation. J. Biol. Chem., 282, 9323-9334.
24. Larsson, S.C. et al. (2004) Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am. J. Clin. Nutr., 79, 935-945.
25. Gleissman, H. et al. (2010) Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates. FASEB J., 24, 906-915.
26. Sun, H. et al. (2005) Omega-3 polyunsaturated fatty acids regulate syndecan-1 expression in human breast cancer cells. Cancer Res., 65, 4442-4447.
27. Serhan, C.N. et al. (2004) Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat., 73, 155-172.
28. Stables, M.J. et al. (2011) Old and new generation lipid mediators in acute inflammation and resolution. Prog. Lipid Res., 50, 35-51.
29. Calder, P.C. (2009) Polyunsaturated fatty acids and inflammatory processes: New twists in an old tale. Biochimie, 91, 791-795.
30. Lu, Y. et al. (2010) Novel 14, 21-dihydroxy-docosahexaenoic acids: structures, formation pathways, and enhancement of wound healing. J. Lipid Res., 51, 923-932.
31. Morgan, L.T. et al. (2010) Thrombin-activated human platelets acutely generate oxidized docosahexaenoic-acid-containing phospholipids via 12-lipoxygenase. Biochem. J., 431, 141-148.
32. Berquin, I.M. et al. (2007) Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. J. Clin. Invest., 117, 1866-1875.
33. Serhan, C.N. et al. (2005) Resolution of inflammation: the beginning programs the end. Nat. Immunol., 6, 1191-1197.
34. Aveldaño, M.I. et al. (1983) Synthesis of hydroxy fatty acids from 4, 7, 10, 13, 16, 19-[1-14C] docosahexaenoic acid by human platelets. J. Biol. Chem., 258, 9339-9343.
35. Sperling, R.I. (1998) The effects of dietary n-3 polyunsaturated fatty acids on neutrophils. Proc. Nutr. Soc., 57, 527-534.
36. Yang, Y.J. et al. (1999) Comparison of fatty acid profiles in the serum of patients with prostate cancer and benign prostatic hyperplasia. Clin. Biochem., 32, 405-409.
37. Mamalakis, G. et al. (2002) Prostate cancer vs hyperplasia: relationships with prostatic and adipose tissue fatty acid composition. Prostaglandins Leukot. Essent. Fatty Acids, 66, 467-477.
38. Brown, M.D. et al. (2006) Promotion of prostatic metastatic migration towards human bone marrow stoma by Omega 6 and its inhibition by Omega 3 PUFAs. Br. J. Cancer, 94, 842-853.
39. O'Flaherty, J.T. et al. (2012) 15-lipoxygenase metabolites of docosahexaenoic Acid inhibit prostate cancer cell proliferation and survival. PLoS ONE, 7, e45480.
40. Liebersbach, B.F. et al. (1994) Expression of syndecan-1 inhibits cell invasion into type I collagen. J. Biol. Chem., 269, 20013-20019.
41. Liu, W. et al. (1998) Heparan sulfate proteoglycans as adhesive and antiinvasive molecules. Syndecans and glypican have distinct functions. J. Biol. Chem., 273, 22825-22832.
42. Couchman, J.R. (2003) Syndecans: proteoglycan regulators of cell-surface microdomains? Nat. Rev. Mol. Cell Biol., 4, 926-937.
43. Inki, P. et al. (1996) The role of syndecan-1 in malignancies. Ann. Med., 28, 63-67.
44. Rapraeger, A.C. (2000) Syndecan-regulated receptor signaling. J. Cell Biol., 149, 995-998.
45. Contreras, H.R. et al. (2010) The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol. Oncol., 28, 534-540.
46. Kiviniemi, J. et al. (2004) Altered expression of syndecan-1 in prostate cancer. APMIS, 112, 89-97.
47. Mimeault, M. et al. (2006) Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis, 27, 1-22.
48. Pollack, A. et al. (1997) Quiescence in R3327-G rat prostate tumors after androgen ablation. Cancer Res., 57, 2493-2500.
49. Westin, P. et al. (1995) Castration therapy rapidly induces apoptosis in a minority and decreases cell proliferation in a majority of human prostatic tumors. Am. J. Pathol., 146, 1368-1375.
50. Bruckheimer, E.M. et al. (2000) Apoptosis in prostate carcinogenesis. A growth regulator and a therapeutic target. Cell Tissue Res., 301, 153-162.
51. Sapieha, P. et al. (2011) 5-Lipoxygenase metabolite 4-HDHA is a mediator of the antiangiogenic effect of ω-3 polyunsaturated fatty acids. Sci. Transl. Med., 3, 69ra12.
52. Birbach, A. et al. (2011) Persistent inflammation leads to proliferative neoplasia and loss of smooth muscle cells in a prostate tumor model. Neoplasia, 13, 692-703.
53. Vasto, S. et al. (2008) Inflammation and prostate cancer. Future Oncol., 4, 637-645.
54. Huss, W.J. et al. (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res., 61, 2736-2743.
55. Aragon-Ching, J.B. et al. (2010) Angiogenesis inhibition in prostate cancer: current uses and future promises. J. Oncol., 2010, 361836.